|By PR Newswire||
|December 26, 2012 12:39 PM EST||
Part 1: Overview, Progress Toward Stopping MS
NEW YORK, Dec. 26, 2012 /PRNewswire-USNewswire/ -- MS research continued to advance on many fronts in 2012. This year saw:
- The approval of a second oral therapy for relapsing forms of MS and other emerging treatments progressing through the development pipeline;
- The launch of the International Progressive MS Collaborative, the largest effort to date to speed research to stop progressive forms of MS;
- The discovery of what could be a target of the immune attack in people with MS may lead to new understanding of the disease and new treatment strategies;
- The completion of the first human trial of an experimental therapy targeting myelin repair;
- Progress in restoring functions using innovative rehabilitation techniques, including memory enhancement using a technique involving stories and imagery to solidify learning, and improving balance and mobility with specific exercises;and
- Advances in uncovering MS triggering factors, bringing us closer to finding ways to prevent the disease; and many other advances pushing us closer to a world free of MS.
The National MS Society continues to propel research forward with a comprehensive strategy aimed at stopping MS, restoring function and ending MS forever (http://www.nationalmssociety.org/research/index.aspx):
- This year we invested $44 million in over 350 new and ongoing projects;
- Projects include everything from discovery research to the Society's drug development efforts through Fast Forward® (www.fastforward.org).
- Read about recently launched research. (http://www.nationalmssociety.org/research/about-our-research-programs/download.aspx?id=44468)
In the world's largest meeting dedicated to MS research, over 7,000 scientists convened in Lyon, France to present findings at ECTRIMS (European Committee for Treatment and Research in MS). Over 1250 studies covering virtually every aspect of research were presented:
- Read a summary http://www.nationalmssociety.org/news/news-detail/index.aspx?nid=7052 and blogs http://blog.nationalmssociety.org/search/label/ECTRIMS
View videos on specific ECTRIMS topics http://www.youtube.com/playlist?list=PLnPWMdCPZiBbT4OEEunsWbzFTkWNoguQD&feature=addto
PROGRESS TOWARD STOPPING MS
The Society continued to invest in research to stop MS, including:
- Funding of clinical trials:
- Testing whether vitamin D, or the sex hormone estriol, or the probiotic approach of a sports drink containing parasite eggs, can reduce MS immune attacks
- Determining if treatments available for other disorders, such as riluzole (a treatment for ALS or Lou Gehrig's disease) or phenytoin (a treatment for epilepsy), or the antioxidants lipoic acid or green tea extract, can protect the nervous system from damage.
- Supporting a syndicate formed in the United Kingdom to conduct innovative clinical trials of neuroprotective drugs in secondary-progressive MS.
- New projects focusing on discovering "biomarkers" to aid better diagnosis and treatment decisions;
- Collaboration in a cross-disease drug screening initiative aimed at discovering the potential of compounds to stop nerve degeneration and protect the brain from harm;
- In partnership with Merck Serono, Fast Forward provided funding for lab research to discover small molecules that can deliver therapies to areas of nervous system damage and protect against that damage in MS.
Other important 2012 results toward stopping MS include:
FDA Approves Oral Aubagio® (Teriflunomide, Genzyme, a Sanofi company)– The once-daily pill was approved as a disease-modifying therapy for relapsing forms of MS. Aubagio is the second oral disease-modifying therapy approved for the treatment of MS, and it became available for prescription in October 2012 in the U.S. http://www.nationalmssociety.org/news/news-detail/index.aspx?nid=6864
Two potential therapies are before FDA –
- Biogen Idec applied to the FDA for approval of BG-12 to treat relapsing MS. This oral therapy showed benefits against relapses and other MS activity in recent trials. The FDA review is underway (http://www.nationalmssociety.org/news/news-detail/index.aspx?nid=6015).
- Genzyme applied for approval of alemtuzumab to treat relapsing MS, based on positive results from several clinical trials. It is given by a cycle of IV infusions once per year. The FDA asked the company to resubmit its application. http://nationalmssociety.org/news/news-detail/index.aspx?nid=6496
Tysabri® label updated to include lab test to enhance treatment decisions – The test detects antibodies to the JC virus and can help determine a person's risk of developing PML, a severe brain infection that has emerged in some people who have taken Tysabri (natalizumab, Biogen Idec and Elan). The test should enhance the ability of people with MS to weigh risks and benefits of this therapy. http://www.nationalmssociety.org/news/news-detail/index.aspx?nid=5887
Clinical trials discussed at ECTRIMS 2012 – Positive results from trials of statins (cholesterol-reducing medication) and Tysabri in progressive forms of MS, a new approach called AIN457 for treating relapsing MS, and results from phase II and III clinical trials of therapies were among results presented at ECTRIMS focusing on stopping MS. http://www.nationalmssociety.org/news/news-detail/index.aspx?nid=7052
Phase II results of ocrelizumab in relapsing MS – Experimental ocrelizumab (Genentech), given intravenously, significantly reduced disease activity on MRI scans in a study of 218 people with relapsing-remitting MS. One person died due to brain edema; the relation of this death to the medication is unclear. Additional research, now going on in primary-progressive MS and relapsing-remitting MS, is needed to further determine this therapy's safety and benefits. http://www.nationalmssociety.org/research/research-news/news-detail/index.aspx?nid=5659
Another step toward personalized medicine in MS – Harvard researchers discovered that differences in active genes that are detectable in blood samples may be used to group people with MS into categories that predict disease course and response to therapy. Further research is needed, but it represents an early step toward personalized medicine in MS. http://www.nationalmssociety.org/news/news-detail/index.aspx?nid=6941
New approach to stopping MS – Researchers at Northwestern University have developed an innovative strategy for selectively inhibiting the immune attack in MS using tiny "nanoparticles" that were able to reduce disease activity in mice. The team is now planning a phase I clinical trial of this new technology. http://www.nationalmssociety.org/news/news-detail/index.aspx?nid=7126
Possible target of immune attacks in some people with MS identified – An immune response to a protein – called "KIR4.1," which is found on several types of brain cells – was observed in the serum of 47% of people with MS. Further research is needed to confirm and understand these findings, which were the result co-funding by the National MS Society. http://nationalmssociety.org/news/news-detail/index.aspx?nid=6619
MS Societies worldwide collaborate to stop MS progression – The newly formed International Progressive MS Collaborative published a paper outlining challenges and identifying key research priorities to propel efforts to stop MS progression. http://www.nationalmssociety.org/news/news-detail/index.aspx?nid=6847
Stress management reduces MS activity – A 24-week stress management program reduced disease activity on MRI scans significantly more than in a control group, in a study at Northwestern University involving 121 people with relapsing MS. However, the benefits appeared to disappear after the weekly in-person stress management sessions were completed. Future studies should provide more clarity for optimizing the potential benefits of stress management. http://www.nationalmssociety.org/news/news-detail/index.aspx?nid=6629
Society launches project to change how MS disability and progression are measured – This cross-sector collaboration has the goal of developing new or improved tools that will be able to track benefits of therapies more quickly in people so that new therapies to stop MS progression may be tested using better assessment tools that are accepted by drug regulatory agencies. http://nationalmssociety.org/news/news-detail/index.aspx?nid=6777
Researchers co-funded by the National MS Society discover possible mechanism for MS damage to nerve tissue – The University of California, San Francisco researchers found that a blood-clotting protein called fibrinogen may play an early role in triggering inflammation that damages nerve fibers in a mouse model of MS. This points to a role for fibrinogen in stimulating inflammation by cells called microglia. If confirmed, targeting the interaction of fibrinogen and microglia may prove to be a novel strategy for stopping MS damage in its tracks. http://www.nationalmssociety.org/news/news-detail/index.aspx?nid=7157
Save this date January 30, 2013, 2:00 – 3:00 p.m. ET and sign up for the live webcast, "From the Frontlines: New Avenues In MS Research for 2013." Visit the National MS Society website.
About Multiple Sclerosis
Multiple sclerosis, an unpredictable, often disabling disease of the central nervous system, interrupts the flow of information within the brain, and between the brain and body. Symptoms range from numbness and tingling to blindness and paralysis. The progress, severity and specific symptoms of MS in any one person cannot yet be predicted, but advances in research and treatment are moving us closer to a world free of MS. Most people with MS are diagnosed between the ages of 20 and 50, with at least two to three times more women than men being diagnosed with the disease. MS affects more than 400,000 people in the U.S. and over 2.1 million worldwide.
About the National Multiple Sclerosis Society
The National MS Society addresses the challenges of each person affected by MS. To fulfill this mission, the Society funds cutting-edge research, drives change through advocacy, facilitates professional education, collaborates with MS organizations around the world, and provides programs and services designed to help people with MS and their families move forward with their lives. In 2011 alone, through its national office and 50-state network of chapters, the Society devoted $164 million to programs and services that assisted more than one million people. To move us closer to a world free of MS, the Society also invested $40 million to support more than 325 new and ongoing research projects around the world. The Society is dedicated to achieving a world free of MS. Join the movement at www.nationalMSsociety.org.
SOURCE National Multiple Sclerosis Society
For basic one-to-one voice or video calling solutions, WebRTC has proven to be a very powerful technology. Although WebRTC’s core functionality is to provide secure, real-time p2p media streaming, leveraging native platform features and server-side components brings up new communication capabilities for web and native mobile applications, allowing for advanced multi-user use cases such as video broadcasting, conferencing, and media recording.
Oct. 21, 2016 05:00 AM EDT Reads: 3,902
Without lifecycle traceability and visibility across the tool chain, stakeholders from Planning-to-Ops have limited insight and answers to who, what, when, why and how across the DevOps lifecycle. This impacts the ability to deliver high quality software at the needed velocity to drive positive business outcomes. In his general session at @DevOpsSummit at 19th Cloud Expo, Eric Robertson, General Manager at CollabNet, will discuss how customers are able to achieve a level of transparency that e...
Oct. 21, 2016 04:45 AM EDT Reads: 379
Fifty billion connected devices and still no winning protocols standards. HTTP, WebSockets, MQTT, and CoAP seem to be leading in the IoT protocol race at the moment but many more protocols are getting introduced on a regular basis. Each protocol has its pros and cons depending on the nature of the communications. Does there really need to be only one protocol to rule them all? Of course not. In his session at @ThingsExpo, Chris Matthieu, co-founder and CTO of Octoblu, walk you through how Oct...
Oct. 21, 2016 04:30 AM EDT Reads: 3,062
DevOps is speeding towards the IT world like a freight train and the hype around it is deafening. There is no reason to be afraid of this change as it is the natural reaction to the agile movement that revolutionized development just a few years ago. By definition, DevOps is the natural alignment of IT performance to business profitability. The relevance of this has yet to be quantified but it has been suggested that the route to the CEO’s chair will come from the IT leaders that successfully ma...
Oct. 21, 2016 04:30 AM EDT Reads: 16,193
Major trends and emerging technologies – from virtual reality and IoT, to Big Data and algorithms – are helping organizations innovate in the digital era. However, to create real business value, IT must think beyond the ‘what’ of digital transformation to the ‘how’ to harness emerging trends, innovation and disruption. Architecture is the key that underpins and ties all these efforts together. In the digital age, it’s important to invest in architecture, extend the enterprise footprint to the cl...
Oct. 21, 2016 04:15 AM EDT Reads: 1,700
Almost everyone sees the potential of Internet of Things but how can businesses truly unlock that potential. The key will be in the ability to discover business insight in the midst of an ocean of Big Data generated from billions of embedded devices via Systems of Discover. Businesses will also need to ensure that they can sustain that insight by leveraging the cloud for global reach, scale and elasticity.
Oct. 21, 2016 04:00 AM EDT Reads: 10,925
@DevOpsSummit has been named the ‘Top DevOps Influencer' by iTrend. iTrend processes millions of conversations, tweets, interactions, news articles, press releases, blog posts - and extract meaning form them and analyzes mobile and desktop software platforms used to communicate, various metadata (such as geo location), and automation tools. In overall placement, @DevOpsSummit ranked as the number one ‘DevOps Influencer' followed by @CloudExpo at third, and @MicroservicesE at 24th.
Oct. 21, 2016 03:30 AM EDT Reads: 3,727
A critical component of any IoT project is what to do with all the data being generated. This data needs to be captured, processed, structured, and stored in a way to facilitate different kinds of queries. Traditional data warehouse and analytical systems are mature technologies that can be used to handle certain kinds of queries, but they are not always well suited to many problems, particularly when there is a need for real-time insights.
Oct. 21, 2016 03:15 AM EDT Reads: 3,834
One of biggest questions about Big Data is “How do we harness all that information for business use quickly and effectively?” Geographic Information Systems (GIS) or spatial technology is about more than making maps, but adding critical context and meaning to data of all types, coming from all different channels – even sensors. In his session at @ThingsExpo, William (Bill) Meehan, director of utility solutions for Esri, will take a closer look at the current state of spatial technology and ar...
Oct. 21, 2016 03:15 AM EDT Reads: 1,642
Without lifecycle traceability and visibility across the tool chain, stakeholders from Planning-to-Ops have limited insight and answers to who, what, when, why and how across the DevOps lifecycle. This impacts the ability to deliver high quality software at the needed velocity to drive positive business outcomes. In his session at @DevOpsSummit 19th Cloud Expo, Eric Robertson, General Manager at CollabNet, will show how customers are able to achieve a level of transparency that enables everyon...
Oct. 21, 2016 02:30 AM EDT Reads: 1,204
Explosive growth in connected devices. Enormous amounts of data for collection and analysis. Critical use of data for split-second decision making and actionable information. All three are factors in making the Internet of Things a reality. Yet, any one factor would have an IT organization pondering its infrastructure strategy. How should your organization enhance its IT framework to enable an Internet of Things implementation? In his session at @ThingsExpo, James Kirkland, Red Hat's Chief Arch...
Oct. 21, 2016 02:00 AM EDT Reads: 5,897
SYS-CON Events announced today that Interface Masters Technologies, a leader in Network Visibility and Uptime Solutions, will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Interface Masters Technologies is a leading vendor in the network monitoring and high speed networking markets. Based in the heart of Silicon Valley, Interface Masters' expertise lies in Gigabit, 10 Gigabit and 40 Gigabit Eth...
Oct. 21, 2016 01:45 AM EDT Reads: 3,258
The IoT industry is now at a crossroads, between the fast-paced innovation of technologies and the pending mass adoption by global enterprises. The complexity of combining rapidly evolving technologies and the need to establish practices for market acceleration pose a strong challenge to global enterprises as well as IoT vendors. In his session at @ThingsExpo, Clark Smith, senior product manager for Numerex, will discuss how Numerex, as an experienced, established IoT provider, has embraced a ...
Oct. 21, 2016 01:30 AM EDT Reads: 863
As software becomes more and more complex, we, as software developers, have been splitting up our code into smaller and smaller components. This is also true for the environment in which we run our code: going from bare metal, to VMs to the modern-day Cloud Native world of containers, schedulers and microservices. While we have figured out how to run containerized applications in the cloud using schedulers, we've yet to come up with a good solution to bridge the gap between getting your conta...
Oct. 21, 2016 01:30 AM EDT Reads: 1,346
Everyone knows that truly innovative companies learn as they go along, pushing boundaries in response to market changes and demands. What's more of a mystery is how to balance innovation on a fresh platform built from scratch with the legacy tech stack, product suite and customers that continue to serve as the business' foundation. In his General Session at 19th Cloud Expo, Michael Chambliss, Head of Engineering at ReadyTalk, will discuss why and how ReadyTalk diverted from healthy revenue an...
Oct. 21, 2016 01:15 AM EDT Reads: 2,909